Key result
Omecamtiv rescues Myosin VI mutant processivity by slowing actin-independent phosphate release.
Why the study?
The D179Y mutation in Myosin VI impairs processive motion and functional activity through elevated phosphate release, but the mechanism of this effect and how omecamtiv modulates it remained to be explored.
No takes yet. Share an insight, caveat, or question.
D179Y mutation elevates phosphate release and abolishes myosin VI processivity; leaves open structural mechanisms of deafness pending experimental confirmation.
Halder et al. (2025) studied Myosin VI D179Y mutation. Omecamtiv was evaluated on Phosphate release rate and processivity. Omecamtiv rescues the processivity of the Myosin VI D179Y mutant by slowing down actin-independent phosphate release through altered P-loop interactions.